Adaptive Biotechnologies (ADPT) Could Be 6% Undervalued Following Its ClonoSEQ Growth Narrative
Adaptive Biotechnologies (ADPT) is back on watch after recent share price moves, with the stock last closing at US$26.49. Investors are reassessing the business as fresh performance data and valuation signals come into focus.
Recent trading has been choppy. Adaptive Biotechnologies has a 1 day share price return of 1.53%, a 7 day share price return down 6.56%, a 90 day share price return of 25.78%, and a year to date share price gain of 66.50%. The company also has a 1 year total shareholder return of 74.62% and a 3 year total shareholder return of more than 5x, which signals strong longer term momentum despite shorter term pullbacks.
Scan how Adaptive Biotechnologies stacks up against other high momentum health and tech plays by reviewing our hand picked 20 high quality undiscovered gems in this corner of the market.
After a sharp rebound and a last close of US$26.49, Adaptive Biotechnologies now trades only modestly below analyst targets but at a premium to some intrinsic estimates. Where does fair value realistically sit within that spread?
Most Popular Narrative: 6% Undervalued
At a last close of $26.49, the most followed narrative pegs Adaptive Biotechnologies fair value at $28.31, leaving a small valuation gap that rests on how its cancer testing franchise scales and gets paid for.
Accelerating integration of clonoSEQ into electronic medical records (EMRs) across both academic and community settings, as well as the major rollout with Flatiron's OncoEMR and expansion through partnerships like NeoGenomics, streamlines ordering and supports recurring test usage. This integration is expected to drive strong multi-year clinical volume growth and recurring revenue.
See why 8 investors see Adaptive Biotechnologies as 6% undervalued.
Result: Fair Value of $28.31 (UNDERVALUED)
Still, if CMS reimbursement decisions or key partnerships such as Genentech or NeoGenomics disappoint, that could quickly undermine the current Adaptive Biotechnologies narrative.
Find out about the key risks to this Adaptive Biotechnologies narrative.
Another View: What Multiples Say About Adaptive Biotechnologies
The story looks different once you step away from analyst targets and look at plain P/S math. Adaptive Biotechnologies trades at a P/S of 13.7x, compared with 4.4x for the US Life Sciences group and a fair ratio of 5.1x that the market could move toward. That premium signals meaningful valuation risk if expectations cool rather than the clean 6% upside suggested by the consensus target. Which lens do you trust more when you weigh your next move?
See what the numbers say about this price in our valuation breakdown, then pressure test your own view of Adaptive Biotechnologies using that context See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this mix of enthusiasm and concern feels familiar, take it as a cue to act promptly and evaluate the trade off for yourself using the 2 key rewards and 1 important warning sign.
Looking for more investment ideas beyond Adaptive Biotechnologies?
If Adaptive Biotechnologies has your attention, do not stop there. Use Simply Wall Street’s screeners to quickly surface other opportunities before they move without you.
- Target potential value by scanning companies that combine quality fundamentals with pricing that still looks appealing using our 28 high quality undervalued stocks.
- Focus on staying power and peace of mind by reviewing a 31 resilient stocks with low risk scores that filters for resilience and lower overall risk profiles.
- Balance potential return with financial resilience by concentrating on businesses with healthier funding and cleaner accounts in our list of solid balance sheet and fundamentals (25 results).
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com